RedShiftBio
Life sciences company developing Microfluidic Modulation Spectroscopy (MMS) technology to measure previously undetectable structural changes in biomolecules for biopharmaceutical development.
Website
https://www.redshiftbio.comLocation
Burlington, Massachusetts, USA
Founded
2015
Investors
1
Categories
biotech, biomolecules, structural-biology, analytical-technology
Notes
RedShiftBio is developing innovative analytical technology for measuring structural changes in biomolecules that were previously undetectable. The company's Microfluidic Modulation Spectroscopy (MMS) platform provides unprecedented sensitivity for characterizing proteins and other biologics.
RedShiftBio's technology is used by biopharmaceutical companies for drug development, formulation optimization, and quality control of biological therapeutics.
Team
- Simon Bunce - Chief Executive Officer
- Leadership team with expertise in analytical instrumentation and biopharma
Additional Research Findings
- Founded in 2015 in Burlington, Massachusetts
- Proprietary Microfluidic Modulation Spectroscopy (MMS) technology
- Focus on protein characterization and structural analysis
- Applications in biopharmaceutical development
- Measures protein higher-order structure
- Used for formulation development and stability studies
- Enables detection of subtle structural changes
- Platform includes Aurora instrument
Sources
Investors
| Name | Location | Type | Stages | Portfolio |
|---|---|---|---|---|
| Illumina Ventures | San Francisco, California, USA | biotech-focused | seedseries-a+1 | 32 |